title: Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients.
abstract: We evaluated cerebral glucose metabolism (CMRglc) and cerebrospinal fluid (CSF) levels of tau and beta-amyloid(1-42) (Abeta42), in relation to apolipoprotein E (ApoE) genotype, in patients with mild Alzheimer disease (AD) treated with rivastigmine (n=11) and tacrine (n=16) for 1 year; and two untreated AD groups. The rivastigmine-treated AD patients showed a significant increase in CMRglc as compared to both tacrine-treated and untreated AD subjects. The rivastigmine-treated AD group showed no change in CSF-tau levels after 1 year, while in contrast a significant increase as seen in tacrine-treated and untreated AD patients. The CSF-tau changes were mainly seen in ApoE epsilon4 carriers. There was no significant change in Abeta42 after 1-year treatment with either rivastigmine or tacrine. This study shows that the two long-term cholinesterase inhibitor treatments exert different effects on biological markers for AD.
authors.affiliation: Karolinska Institutet, Department of Clinical Neuroscience Occupational Therapy and Elderly Care Research (NEUROTEC), Division of Molecular Neuropharmacology, Huddinge University Hospital, B84, 141 86, Stockholm, Sweden.
authors.forename: E
authors.initials: E
authors.lastname: Stefanova
authors.forename: K
authors.initials: K
authors.lastname: Blennow
authors.forename: O
authors.initials: O
authors.lastname: Almkvist
authors.forename: E
authors.initials: E
authors.lastname: Hellström-Lindahl
authors.forename: A
authors.initials: A
authors.lastname: Nordberg
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid / Q000188:drug therapy* / Q000378:metabolism; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D053329:Apolipoprotein E2; D053327:Apolipoprotein E4; D001057:Apolipoproteins E / Q000235:genetics*; D015415:Biomarkers / Q000032:analysis; D001921:Brain / Q000378:metabolism*; D002219:Carbamates / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005838:Genotype; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000134:cerebrospinal fluid*; D048448:Phenylcarbamates; D000068836:Rivastigmine; D013619:Tacrine / Q000627:therapeutic use; D016875:tau Proteins / Q000235:genetics*
chemical_list: D016229:Amyloid beta-Peptides; D053329:Apolipoprotein E2; D053327:Apolipoprotein E4; D001057:Apolipoproteins E; D015415:Biomarkers; D002219:Carbamates; D002800:Cholinesterase Inhibitors; D010446:Peptide Fragments; D048448:Phenylcarbamates; C075222:amyloid beta-protein (1-42); D016875:tau Proteins; D013619:Tacrine; D005947:Glucose; D000068836:Rivastigmine